Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

799 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, Malloff CA, Lam WL, Squire JA, Pintilie M, Sykes J, Ramnarine VR, Meng A, Ahmed O, Jurisica I, van der Kwast T, Bristow RG. Locke JA, et al. Among authors: sykes j. Clin Cancer Res. 2012 Jan 1;18(1):308-16. doi: 10.1158/1078-0432.CCR-11-2147. Epub 2011 Nov 2. Clin Cancer Res. 2012. PMID: 22048240
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.
Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Guns ET, van der Kwast T, Milosevic M, Bristow RG. Locke JA, et al. Among authors: sykes j. Prostate. 2012 Sep 1;72(12):1295-305. doi: 10.1002/pros.22478. Epub 2011 Dec 27. Prostate. 2012. PMID: 22213075 Clinical Trial.
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Milosevic M, Pintilie M, van der Kwast T, Bristow RG. Zafarana G, et al. Among authors: sykes j. Cancer. 2012 Aug 15;118(16):4053-62. doi: 10.1002/cncr.26729. Epub 2012 Jan 26. Cancer. 2012. PMID: 22281794 Free article.
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG. Dal Pra A, et al. Among authors: sykes j. Clin Cancer Res. 2013 Sep 15;19(18):5202-9. doi: 10.1158/1078-0432.CCR-13-1049. Epub 2013 Aug 5. Clin Cancer Res. 2013. PMID: 23918607
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DYF, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG. Lalonde E, et al. Among authors: sykes j. Lancet Oncol. 2014 Dec;15(13):1521-1532. doi: 10.1016/S1470-2045(14)71021-6. Epub 2014 Nov 13. Lancet Oncol. 2014. PMID: 25456371 Free article.
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.
McKee CM, Xu D, Cao Y, Kabraji S, Allen D, Kersemans V, Beech J, Smart S, Hamdy F, Ishkanian A, Sykes J, Pintile M, Milosevic M, van der Kwast T, Zafarana G, Ramnarine VR, Jurisica I, Mallof C, Lam W, Bristow RG, Muschel RJ. McKee CM, et al. Among authors: sykes j. J Clin Invest. 2012 Nov;122(11):4025-36. doi: 10.1172/JCI59348. Epub 2012 Oct 8. J Clin Invest. 2012. PMID: 23041623 Free PMC article.
799 results